Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(13%)
Results Posted
150%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
2
25%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(2)
Terminated(5)

Detailed Status

Withdrawn4
Completed2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 24 (57.1%)
Phase 32 (28.6%)

Trials by Status

withdrawn450%
active_not_recruiting113%
terminated113%
completed225%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_3

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

NCT04810091
completedphase_2

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

NCT03910387
terminatedphase_2

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

NCT03790111
withdrawnphase_2

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NCT04713202
withdrawnphase_2

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

NCT04776876
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04810091Phase 3

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Active Not Recruiting
NCT03910387Phase 2

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Completed
NCT03790111Phase 2

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Terminated
NCT04713202Phase 2

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

Withdrawn
NCT04776876Phase 2

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

Withdrawn
NCT04034745

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Withdrawn
NCT04065165Phase 3

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

Withdrawn
NCT03423446Phase 1

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8